BR112018001816A2 - “análogos de adamantil ureias como inibidores solúveis da epóxido hidrolase - Google Patents

“análogos de adamantil ureias como inibidores solúveis da epóxido hidrolase

Info

Publication number
BR112018001816A2
BR112018001816A2 BR112018001816A BR112018001816A BR112018001816A2 BR 112018001816 A2 BR112018001816 A2 BR 112018001816A2 BR 112018001816 A BR112018001816 A BR 112018001816A BR 112018001816 A BR112018001816 A BR 112018001816A BR 112018001816 A2 BR112018001816 A2 BR 112018001816A2
Authority
BR
Brazil
Prior art keywords
trifluoromethylphenyl
epoxide hydrolase
phenyl
adamantil
urea analogs
Prior art date
Application number
BR112018001816A
Other languages
English (en)
Inventor
Valverde Murillo Elena
VÁZQUEZ CARRERA Manuel
Leiva Martínez Rosana
CODONY GISBERT Sandra
Vázquez Cruz Santiago
Original Assignee
Univ Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Barcelona filed Critical Univ Barcelona
Publication of BR112018001816A2 publication Critical patent/BR112018001816A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

n- (2-oxaadamantan-1-il) ureas de fórmula i, em que r3 é h, alquilo c1-c3, ciclo-hexilo ou fenilo; r é - [ch2] n -y; n é 0-15; em - [ch2] n - 0-n / 3 dos grupos metileno são opcionalmente substituídos por átomos de oxigénio não adjacentes; e y é um fenilo 3 ou 4-substituído, um ciclo-hexilo com 3 ou 4 substituintes, um piperidin-4-ilo n-substituído, um piperidin-3-ilo n-substituído, um fenilo di- ou tri-fluorosubstituído, 4-cloro-3-trifluorometilfenilo, 3-cloro-4- trifluorometilfenilo, 4-fluoro-3-trifluorometilfenilo ou 3-fluoro-4-trifluorometilfenilo; têm atividades inibitórias de epóxido hidrolase (seh) semelhantes às dos seus análogos de n- (adamantan-1-il) ureia. assim, os compostos são úteis como api para o tratamento de doenças mediadas por seh. além disso, em geral, compostos eu tenho maior solubilidade em água e pontos de fusão mais baixos, o que os torna mais promissores do ponto de vista da farmacocinética e formulação.
BR112018001816A 2015-07-28 2016-07-25 “análogos de adamantil ureias como inibidores solúveis da epóxido hidrolase BR112018001816A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15178618 2015-07-28
PCT/EP2016/067620 WO2017017048A1 (en) 2015-07-28 2016-07-25 Analogs of adamantylureas as soluble epoxide hydrolase inhibitors

Publications (1)

Publication Number Publication Date
BR112018001816A2 true BR112018001816A2 (pt) 2018-09-18

Family

ID=53758109

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001816A BR112018001816A2 (pt) 2015-07-28 2016-07-25 “análogos de adamantil ureias como inibidores solúveis da epóxido hidrolase

Country Status (10)

Country Link
US (1) US20200079786A1 (pt)
EP (1) EP3328854A1 (pt)
KR (1) KR20180030706A (pt)
CN (1) CN108349955A (pt)
AU (1) AU2016301027A1 (pt)
BR (1) BR112018001816A2 (pt)
CA (1) CA2993882A1 (pt)
CL (1) CL2018000231A1 (pt)
MX (1) MX2018001135A (pt)
WO (1) WO2017017048A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3584236A1 (en) * 2018-06-20 2019-12-25 Universitat de Barcelona Polycyclic compounds soluble epoxide hydrolase inhibitors
CN113831301B (zh) * 2020-06-08 2023-06-06 沈阳药科大学 苯并噻唑类衍生物及其用途
CN113185451B (zh) * 2021-04-28 2023-09-12 沈阳药科大学 美金刚脲类衍生物及其制备方法和应用
CN113402447B (zh) * 2021-06-22 2022-10-18 沈阳药科大学 一种sEH抑制剂或其药学上可接受的组合物及其制备方法和应用
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH456570A (de) * 1965-11-18 1968-07-31 Geigy Ag J R Verfahren zur Herstellung von neuen substituierten Harnstoffderivaten
US3621100A (en) * 1965-11-18 1971-11-16 Geigy Chem Corp Composition and method for producing a tuberculostatic effect
CA2559665A1 (en) * 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
JP2010504362A (ja) * 2006-09-25 2010-02-12 アレテ セラピューティクス， インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
CN101516838A (zh) * 2006-09-28 2009-08-26 亚瑞特医疗公司 可溶性环氧化物水解酶抑制剂

Also Published As

Publication number Publication date
US20200079786A1 (en) 2020-03-12
KR20180030706A (ko) 2018-03-23
CN108349955A (zh) 2018-07-31
WO2017017048A1 (en) 2017-02-02
CA2993882A1 (en) 2017-02-02
MX2018001135A (es) 2018-05-23
EP3328854A1 (en) 2018-06-06
CL2018000231A1 (es) 2018-07-20
AU2016301027A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
BR112018001816A2 (pt) “análogos de adamantil ureias como inibidores solúveis da epóxido hidrolase
AR120317A2 (es) Compuestos de indolcarboxamida, composiciones farmacéuticas que los contienen y dichos compuestos para uso en el tratamiento de la enfermedad autoinmune o enfermedad inflamatoria crónica
AR109315A1 (es) Composiciones farmacéuticas que contienen derivados de piridona policíclica sustituida y profármaco de las mismas
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
PE20200401A1 (es) Nuevos compuestos como inhibidores de autotaxina y composiciones farmaceuticas que comprenden a los mismos
MY187479A (en) 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
WO2016077464A8 (en) Amino acid derivatives and their uses
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
BR112014030473A2 (pt) novo diazaespirocicloalcano e azaespirocicloalcano
BRPI0506676A (pt) piridazinona uréias como antagonistas de integrinas alfa4
EA201691119A1 (ru) Производные мочевины или их фармакологически приемлемые соли
BR112014001801A2 (pt) indazóis
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
ECSP14030538A (es) Inhibidores de dgat1 de éter cíclico de cabeza de puente
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
PE20211461A1 (es) Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
BR112015027164A2 (pt) novos compostos com tripla atividade de trombólise, antitrombótica e neutralização de radical, e sua síntese, nanoestrutura e uso
BR112015021768A2 (pt) inibidores do vírus da hepatite c
CO2018010787A2 (es) Compuesto de griseofulvina
TR201819155T4 (tr) Yeni izoindolin veya izokinolin bileşikleri, bunların hazırlanması için bir yöntem ve bunları içeren farmasötik bileşimler.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired